The Agrobacterium tumefaciens VirB proteins are postulated to form a transport pore for the transfer of T-DNA. Formation of the transport pore will involve interactions among the VirB proteins. A powerful genetic method to study protein-protein interaction is the yeast two-hybrid assay. To test whether this method can be used to study interactions among the VirB membrane proteins, we studied the interaction of VirB7 and VirB9 in yeast. We recently demonstrated that VirB7 and VirB9 form a protein complex linked by a disulfide bond between cysteine 24 of VirB7 and cysteine 262 of VirB9 (L. Anderson, A. Hertzel, and A. Das, Proc. Natl. Acad. Sci. USA 93:8889-8894, 1996). We now demonstrate that VirB7 and VirB9 interact in yeast, and this interaction does not require the cysteine residues essential for the disulfide linkage. By using defined segments in fusion constructions, we mapped the VirB7 interaction domain of VirB9 to residues 173 to 275. In tumor formation assays, both virB7C24S and virB9C262S expressed from a multicopy plasmid complemented the respective deletion mutation, indicating that the cysteine residues may not be essential for DNA transfer.
Agrobacterium tumefaciens transfers a segment of its tumorinducing (Ti) plasmid DNA upon infection of plant cells (reviewed in reference 15). Expression of the phytohormone biosynthetic genes encoded within the transferred DNA leads to the crown gall tumor phenotype. The transfer of the T-DNA is catalyzed by proteins encoded in the virulence (vir) region of the Ti plasmid (12, 20, 31) . Proteins of the virB operon and one protein encoded in the virD operon, VirD4, are essential for DNA transfer (42) . These proteins also catalyze the transfer of plasmid DNA between two Agrobacterium strains and from Agrobacterium to the yeast Saccharomyces cerevisiae (2, 5, 22, 26) .
The virB operon encodes 11 proteins, 10 of which, VirB2 to VirB11, are essential for DNA transfer (4, 38) . The other one, VirB1, augments transfer efficiency. The presence of one or more hydrophobic segments that can function in membrane spanning and/or as a signal sequence in most VirB proteins suggests that these proteins are membrane proteins or are associated with the bacterial membranes (17, 33, 38) . This hypothesis is supported by biochemical studies that demonstrated that all 11 VirB proteins fractionate with the bacterial membrane (9, 11, 28, 34) . Mutational studies demonstrated that virB is not required for the synthesis of T-strand DNA, the intermediate in T-DNA transfer (32, 35, 43) . The association of the VirB proteins with the bacterial membranes, the essential role of these proteins in DNA transfer, and their requirement in a step(s) beyond the T-strand DNA synthesis led to the hypothesis that the VirB proteins form a transport pore to allow T-strand DNA to move from bacteria to a plant cell. The observations that the transfer proteins of the bacterial conjugal plasmids and the Ptl proteins of the animal pathogen Bordetella pertussis are homologous to the VirB proteins support this hypothesis (18, 23, 40) . The transfer proteins are essential for the conjugal transfer of the plasmid DNA, and the Ptl proteins are essential for the excretion of a toxin protein.
The transport pore for T-DNA transfer is probably a complex structure involving several proteins. Protein-protein interactions are likely to play a major role in the assembly and stabilization of this structure. We recently reported the identification of the first protein complex composed of two VirB proteins (1) . We demonstrated that VirB7 and VirB9 form a covalent complex linked by a disulfide bond. Cysteine 24 of VirB7 and cysteine 262 of VirB9 participate in the disulfide bond formation. Similar results were obtained by Spudich et al. (30) . Since VirB7 is a lipoprotein and is anchored to the outer membrane (8) , it is postulated that the VirB7-VirB9 complex is linked to the inner surface of the outer membrane. In an earlier study, a homooligomer of VirB10 was identified by use of a chemical cross-linker (39) .
Because protein-protein interactions probably play a major role in the organization of the transport pore, the identification of the proteins involved in these interactions is essential to define the assembly and architecture of the pore. A genetic method to study such interactions is the yeast two-hybrid assay (10) . In the last several years, this system has been widely used to identify interacting proteins (reviewed in reference 41). Almost all proteins used in these studies are of cytoplasmic origin. Since all VirB proteins are membrane proteins and very limited information is available on whether the two-hybrid assay can be used to study membrane proteins, we used the VirB7-VirB9 system as a test system to investigate the suitability of this approach to study interactions among the VirB proteins. Since the existence of the VirB7-VirB9 complex has been established by biochemical methods, we considered that this complex will be a good experimental system for analysis by the yeast two-hybrid assay. In this study, we demonstrate that VirB7 and VirB9 interact with each other in a yeast two-hybrid assay and define the sequences essential for this interaction.
MATERIALS AND METHODS
Strains and plasmids. The strains and plasmids used in this study are listed in Table 1 . For the yeast two-hybrid assays, plasmids pEG202 and pJG4-5 were used for the construction of the bait and activator fusions (14) . Plasmid pAD1446, a lexA-virB9 fusion plasmid, was constructed by cloning a 870-bp NaeI fragment that encodes the C-terminal 267 residues of VirB9 into a filled-in BamHI site of plasmid pEG202. The fusion protein lacks the first 27 residues of VirB9. Plasmid pAD1447, an activator-virB7 fusion plasmid, and plasmid pAD1483, a lexA-virB7 fusion plasmid, were constructed by cloning a ϳ250-bp EcoRI fragment encoding residues 11 to 55 of VirB7 into the unique EcoRI site of pJG4-5 and pEG202, respectively. The fragment was generated by PCR amplification of pAD1399 with a virB7-specific synthetic oligonucleotide and the m13/pUC reverse sequencing primer as the primers followed by digestion with EcoRI (24) . Plasmids pAD1486 and pAD1487 are similar to pAD1447 and pAD1446 except that they contain virB7C24S and virB9C262S, respectively. Plasmid pAD1494, an activator-virB9 fusion plasmid, was constructed by cloning the ϳ0.9-kb EcoRI-XhoI fragment of pAD1446 into plasmid pJG4-5. Derivatives of plasmid pAD1494 that contained defined sequences from the C-terminal end of VirB9 were constructed by cloning the appropriate fragments generated by PCR amplification (24) . The junction regions of all fusion plasmids were confirmed by DNA sequence analysis (6, 25) .
For the expression of the virB genes, the coding sequence of the gene(s) of (21) . Plasmid pAD1424 contains virB7 and virB8. Plasmids pLA21, pLA26, and pLA27 contain both virB8 and virB9 plus either virB7, virB7C15S, or virB7C24S, respectively. Two-hybrid assay. Plasmid DNA was introduced into yeast by transformation (13) . Briefly, a fresh colony grown on a yeast extract-peptone-dextrose plate was resuspended in 30 l of 0.1 M lithium acetate. Nine volumes of a solution containing 0.1 M lithium acetate, 45% polyethylene glycol-3350, 1 mM EDTA, and 10 mM Tris-HCl (pH 8) was added. DNA (1 to 5 g) was added to the cell suspension, mixed by vortexing, and incubated overnight at room temperature. The next day, cells were plated on selective medium.
For two-hybrid assays, we constructed a yeast strain, AD842, by introducing the plasmid pSH18-34 that contains a reporter Gal1-LexAop-lacZ gene into S. cerevisiae EGY48 by transformation. Derivatives of the bait and the activator plasmids containing the appropriate gene fusions were then introduced into S. cerevisiae AD842. For control experiments, the vector plasmid was introduced into the strain containing a fusion gene. The interaction between two proteins was tested by assaying for a blue colony on plates containing the chromogenic substrate X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside) and by growth on a leucine-free medium. The host strain contains a Gal1-LexAop-leu2 gene on the chromosome. Activation of Gal1 results in a leu ϩ phenotype. For ␤-galactosidase assays, cells were grown overnight in the presence of galactose and raffinose in complete minimal dropout medium lacking uracil, tryptophan, and histidine (13) . Cells were diluted to an A 600 of ϳ0.2 and grown overnight in the same medium. ␤-Galactosidase activity was assayed as described by Miller (19) . The data presented are averages of two independent experiments.
Tumorigenesis assays. The ability of virB7, virB9, and their mutants to complement a deletion in the respective gene was investigated by monitoring tumor formation on Kalanchöe daigremontiana leaves and potato tubers as described previously (29, 37) .
RESULTS AND DISCUSSION
A two-hybrid system to study interactions among the VirB proteins. The vir-mediated DNA transfer of T-DNA from Agrobacterium to plant cells is postulated to occur through a transport pore composed primarily of the VirB proteins. An assembly of the transport pore will require a specific interaction between the VirB proteins. We recently reported that two VirB proteins, VirB7 and VirB9, form a disulfide-linked protein complex (1). Cysteine 24 of VirB7 and cysteine 262 of VirB9 participate in the disulfide bond formation. A powerful genetic method to identify proteins that interact with each other is the two-hybrid assay in the yeast S. cerevisiae (10) . This system has been used successfully to study soluble proteins. We investigated whether this system can be used to define proteinprotein interactions among the VirB membrane proteins. As a test case, we studied the interaction between VirB7 and VirB9.
The system developed by R. Brent and coworkers was used for the two-hybrid assays (13, 14) . The coding region of VirB9 except for that encoding the first 27 residues was cloned into plasmid pEG202 to construct a lexA-virB9 gene fusion, the bait gene. An activator-virB7 fusion was constructed by cloning a DNA fragment encoding the C-terminal 45 residues of VirB7 (residue 11 to the end). To test whether the VirB7 and VirB9 fusion proteins interact with each other, plasmids containing the appropriate fusions were introduced into a yeast strain harboring the reporter genes Gal1-LexAop-leu2 and Gal1-LexAop-lacZ. A strain expressing the LexA-VirB9 fusion and the activator or the activator-VirB7 fusion and LexA did not grow in the absence of leucine and formed white colonies on indicator plates containing X-Gal (Fig. 1) . When both the LexAVirB9 and the activator-VirB7 fusions were expressed in the same host, the recombinant grew in a leucine-free medium and formed blue colonies on the indicator plate. Leucine prototrophy and the formation of a blue colony require activation of the Gal1 promoter, and Gal1 activation requires that the DNA binding and activator domains of the two fusion proteins are positioned together on the DNA. A positive result in these studies indicates that the VirB7 and VirB9 segments of the fusion proteins bring the two functional domains together by protein-protein interactions. These results confirm our earlier observations that VirB7 and VirB9 interact with each other.
Role of the cysteine residues essential for disulfide bond formation in the VirB7-VirB9 interaction. VirB7 and VirB9 form a covalent complex linked by a disulfide bond between cysteine 24 of VirB7 and cysteine 262 of VirB9 (1, 30) . The alteration of the cysteines to serines led to the loss of the disulfide-linked complex; however, what effect, if any, the mutations have on protein function was not assessed in those studies. The success of the two-hybrid assay suggests that the cysteine residues are probably not essential for the VirB7-VirB9 complex formation because the reducing environment of a yeast nucleus is unlikely to support disulfide bond formation. To test this hypothesis, we constructed fusions that contain cysteine-to-serine substitutions in VirB7 and VirB9 and studied the effect of the mutations on reporter gene expression by the two-hybrid assay (Table 2) . A yeast strain expressing LexA-VirB9C262S and activator-VirB7 formed blue colonies FIG. 1. Protein-protein interaction between VirB7 and VirB9. Interaction between VirB7 and VirB9 was monitored by the yeast two-hybrid assay (13) . A yeast strain containing a plasmid(s) that expresses the desired fusion protein was streaked on a plate lacking leucine (LeuϪ) and on one containing X-Gal. The restoration of Gal1 transcription by interaction between two fusion proteins allows expression of a leu2 gene and a reporter lacZ gene. The plasmid contents of the three strains studied are indicated on the figure. LexA, LexA vector plasmid; Act, activator vector plasmid; B9-LexA, LexA-VirB9 fusion; B7-Act, activator-VirB7 fusion. All strains harbor another plasmid containing the Gal1-LexAop-lacZ gene. a Interactions between VirB7, VirB9, and their mutants were monitored by the yeast two-hybrid assay (13) . Expression of the reporter lacZ gene was measured by the method of Miller (19) .
b Data presented are averages of two independent experiments Ϯ standard errors.
on a plate containing X-Gal (data not shown) and showed a high level of ␤-galactosidase activity. Similarly, strains expressing LexA-VirB9 and activator-VirB7C24S had a lac-positive phenotype. A strain that expressed both VirB7C24S and VirB9C262S had a high level of ␤-galactosidase activity, a level comparable to that in a strain expressing both of the wild-type proteins. These results indicate that the cysteine residues that participate in disulfide bond formation are not required for VirB7-VirB9 interaction in yeast.
A 103-residue domain near the C terminus of VirB9 is sufficient for complex formation with VirB7. The yeast two-hybrid system was used to more precisely define the VirB7 interaction domain of VirB9. For our initial analysis, we constructed fusions of VirB9 with LexA and VirB7 with the activator (Fig. 1) . To test whether the reciprocal fusions are also functional, we constructed fusions of VirB7 with LexA and VirB9 with the activator. This combination was not only functional but showed about a fivefold-higher level of ␤-galactosidase activity (Tables  2 and 3) . Because a wide range of activity will allow a more accurate comparison of two fusions, we used this combination for the studies on the identification of the VirB7 interaction domain of VirB9. Several fusions of the acidic activator with defined segments of virB9 were constructed. The ability of a fusion protein to interact with the LexA-VirB7 fusion was tested by monitoring expression of the Gal1-LexA op -lacZ reporter gene (Table 3) . A fusion protein that contains residues 173 to 293 (the end) of VirB9 strongly activated expression of the reporter gene ( Table 3 ), indicating that the first 172 residues of VirB9 are not required for its interaction with VirB7.
Further analysis of the essential region showed that the Cterminal 20 residues are also dispensable (leaving residues 173 to 275). The analysis of additional deletions in the N-terminal region of the interactor domain showed that the deletion of 24 residues in addition to the first 172 (i.e., the first 196 residues) led to a complete loss of interaction. Western blot analysis of the fusion proteins using antihemagglutinin antibodies showed that all strains produced stable fusion proteins (data not shown). Therefore, residues 173 to 275 of VirB9 constitute the minimum interactor domain. Since the disulfide linkage between VirB7 and VirB9 involves VirB9 cysteine 262, a large segment N-terminal to this residue is essential for the interaction with VirB7. The requirement of a relatively large segment of the protein for this interaction suggests that the N-terminal domain lies close to the C-terminal domain in space.
Role of cysteine 24 of VirB7 and cysteine 262 of VirB9 in T-DNA transfer. The ability of the VirB7C24S and VirB9C262S to interact with each other in vivo in yeast suggests that the cysteine residues are not essential for their interaction. If a similar phenomenon occurs in Agrobacterium, these two residues could be dispensable for tumor formation. To test this hypothesis, we determined the ability of the virB7 and virB9 mutants to complement a deletion mutation in the respective gene in tumor formation assays in potato and K. daigremontiana (Table 4 ; Fig. 2) .
Deletion of either virB7 or virB9 renders A. tumefaciens A348 nontumorigenic (4) . In a potato disc assay, the virB7 deletion mutant Agrobacterium A348⌬B7 could be complemented with a plasmid that constitutively expresses virB7 and   FIG. 2 . Complementation of Agrobacterium A348⌬B7. Tumor formation on K. daigremontiana leaves was monitored as described previously (37) . virB genes expressed from the plasmid are abbreviated as follows: B7, virB7; B8, virB8; B9, virB9; B7C15S, virB7C15S; B7C24S, virB7C24S. a Agrobacterium A348⌬B7 and A348⌬B9 have deletions in virB7 and virB9, respectively (4). Tumor formation was measured by a potato disc assay (29, 37) . The value of the complementing strain with a wild-type gene is set at 100%. The numbers of tumors for the A348⌬B7 and A348⌬B9 complementing strains and for A348 were 147 Ϯ 25, 118 Ϯ 11, and 503 Ϯ 118, respectively. The data presented are averages of three independent experiments Ϯ standard errors.
virB8 from the virD promoter (Table 4) . When virB9 was included in the complementing plasmid, a twofold increase in the efficiency of tumor formation was observed. The substitution of virB7C24S for virB7 did not have a significant effect on the complementation ability of the plasmid, indicating that cysteine 24 is not essential for tumor formation. In agreement with a previous study (8) , we found that the cysteine in position 15 (virB7C15S) is essential for VirB7 function. A high level of constitutive expression is not necessary for complementation because vir genes expressed from the inducible virD promoter on a low-copy IncP plasmid, pTJS75, are equally efficient in complementation (data not shown). Studies on the complementation of a virB9 deletion mutant, Agrobacterium A348⌬B9, showed that virB9C262S, a virB9 mutant that cannot form a disulfide linkage, can restore the tumor-forming ability of the mutant, indicating that cysteine 262 of VirB9 is not essential for tumor formation.
The disulfide-linked VirB7-VirB9 complex is postulated to play a major role in the assembly of the transport pore (1, 30) . VirB9 is unstable in the absence of VirB7 (4, 9) . The disulfide linkage between VirB7 and VirB9 has been postulated to be important for the stabilization of VirB9 (9, 30) . The stability of a VirB9 homolog, the B. pertussis PtlF, is affected by PtlI, the VirB7 homolog. PtlI and PtlF, like VirB7 and VirB9, form a disulfide-linked complex (7). Data presented above demonstrate that VirB7C24S and VirB9C262S, mutants that cannot form the disulfide linkage, are active in tumor formation. The disulfide linkage therefore is not an absolute necessity for protein function. Whether it is essential for the stability of VirB9 cannot be addressed from the results of this study. Agrobacterium used in the present study overproduces the plasmid-encoded gene products (1) (data not shown). Consequently, these strains contain a high level of VirB9 and the accumulation of VirB9 in these strains is independent of VirB7.
In potato disc assays, virB7 and virB8 complement Agrobacterium A348⌬B7 (Table 4) . Coexpression of virB9 increased the efficiency of complementation. The role of virB9 in the complementation of this particular mutant was apparent when K. daigremontiana was used as a host plant (Fig. 2) . A previous study showed that on K. daigremontiana, tumor formation by Agrobacterium A348⌬B7 requires coexpression of virB7 and virB8 (4) . Under our assay conditions, these results were difficult to reproduce. We observed that virB7 and virB8 expressed from the virD promoter are unable to complement Agrobacterium A348⌬B7; only occasionally, we observed small tumors. A typical result is shown in Fig. 2 . To determine the requirements for the complementation of Agrobacterium A348⌬B7, we studied the effect of expression of the downstream genes, namely, virB9, virB10, and virB11. We found that in addition to virB7 and virB8, virB9 is essential for the restoration of tumorigenicity of Agrobacterium A348⌬B7 on K. daigremontiana (Fig. 2) . The virB7 mutant virB7C24S, but not virB7C15S, was equally efficient in complementation.
Our observation that virB9 is essential for the complementation of the virB7 deletion mutant Agrobacterium A348⌬B7 in a tumor formation assay on K. daigremontiana leaves does not agree with the previous report that found no such role of virB9 (4) . The two studies differ in the chimeric genes that were used for the expression of the vir genes. While the vir genes were expressed constitutively from the strong virD promoter in our study, the genes were expressed under the control of the E. coli lactose operon promoter in the other study. Second, the genes were expressed from a high-copy plasmid in the present study. The difference in the expression level of the proteins, however, cannot account for the discrepancy in the two studies for several reasons. First, the native virB promoter is a strong promoter, and therefore, under natural induction conditions, the level of the encoded gene products is likely to be high. Second, while the Ti plasmid is present in 1 to 2 copies in the vegetative cell, the copy number of the plasmid is 5-to 10-fold higher in an induced bacterium (36) . Third, vir genes expressed from the inducible virD promoter on the low-copy plasmid pTJS75 are equally efficient in complementation (data not shown). Also, we observed no negative effect of overexpression of the VirB proteins in complementation analysis of several virB mutants.
The best interpretation of our results is that a low level of VirB9 in Agrobacterium A348⌬B7 is sufficient for tumor formation on potato tubers but not on K. daigremontiana. That Agrobacterium A348⌬B7 expresses virB9 at a low level has been reported earlier (9) . We suggest that the reduced level of VirB9 in this strain is not only due to the effect of VirB7 on the stability of VirB9 (4) but also is a consequence of the construction of the deletion mutation. If the stability of VirB9 is the only reason, virB7 expressed from a multicopy plasmid should restore a high level of VirB9 in the cell. Experimental results do not support this prediction (9) . Agrobacterium A348⌬B7 is also defective in virB8 since complementation of this mutant requires virB8 (4; this study).
The aberrant behavior of Agrobacterium A348⌬B7 in the present study and that of Agrobacterium A348⌬B7 and Agrobacterium A348⌬B8 in the previous study (4) led us to reconsider the hypothesis of Ward et al. (38) that the translation of pTiA6 virB8 initiates at bp 6406 and not at bp 6385. The presence of a ribosome binding site sequence at bp 6378 to 6380 (GGA), the lack of one near bp 6406, and a homologous start site for the pTiC58 virB8 suggests that bp 6385 is the translation start site of virB8 (3) . If this is true, Agrobacterium A348⌬B7, which has a deletion of bp 6332 to 6406, will lose the 7 N-terminal residues of VirB8. This can result in an altered expression of virB8 and/or may negatively affect the stability of the mutant protein. In Western blot assays, no VirB8 was detected in Agrobacterium A348⌬B7 (9; unpublished results). A possible consequence of the modulation of virB8 expression is a reduction in the expression of the downstream genes.
Studies presented here demonstrate that VirB7-VirB9 interaction does not require a disulfide linkage and, at least under conditions of overproduction, the disulfide bond is dispensable for tumor formation. The nonessential nature of the cysteine residues can account for the lack of conservation of these residues in certain homologs. The VirB7 and VirB9 homologs in the conjugal plasmid pKM101 that encodes homologs of all 11 VirB proteins do not have a conserved cysteine (23) . While the disulfide linkage is not essential for tumor formation, it may be involved in the stabilization of the complex and in the maintenance of a rigid orientation of the complex to the bacterial membrane.
